Drug intelligence / Profile preview

VBY-129

Development stage: Preclinical
Lead developer: Virobay
Modality: Small Molecules

Overview

VBY-129 is a small-molecule inhibitor of cathepsin proteases currently in preclinical development by Virobay for the treatment of Alzheimer's disease. Cathepsins are a family of lysosomal cysteine proteases that play critical roles in intracellular protein degradation and cellular homeostasis. In the context of Alzheimer's disease, specific cathepsins are implicated in the pathological processing of amyloid precursor protein and the promotion of neuroinflammatory responses. VBY-129 is designed to cross the blood-brain barrier and selectively inhibit these proteases to potentially reduce amyloid burden and neurodegeneration.

Targets

CTSS (Cathepsin S)

Beyond the preview

Go deeper on VBY-129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VBY-129.

Explore the full profile